Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer: A Point of View

12Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The goal of this manuscript is to explore the role of clinical proteomics for detecting mutations in chronic obstructive pulmonary disease (COPD) and lung cancer by mass spectrometry-based technology. COPD and lung cancer caused by smoke inhalation are most likely linked by challenging the immune system via partly shared pathways. Genome-wide association studies have identified several single nucleotide polymorphisms which predispose an increased susceptibility to COPD and lung cancer. In lung cancer, this leads to coding mutations in the affected tissues, development of neoantigens, and different functionality and abundance of proteins in specific pathways. If a similar reasoning can also be applied in COPD will be discussed. The technology of mass spectrometry has developed into an advanced technology for proteome research detecting mutated peptides or proteins and finding relevant molecular mechanisms that will enable predicting the response to immunotherapy in COPD and lung cancer patients.

Author supplied keywords

Cite

CITATION STYLE

APA

Zeneyedpour, L., Dekker, L. J. M., van Sten-van`t Hoff, J. J. M., Burgers, P. C., ten Hacken, N. H. T., & Luider, T. M. (2019). Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer: A Point of View. Proteomics - Clinical Applications, 13(2). https://doi.org/10.1002/prca.201800093

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free